CN103055124A - Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof Download PDFInfo
- Publication number
- CN103055124A CN103055124A CN 201210595150 CN201210595150A CN103055124A CN 103055124 A CN103055124 A CN 103055124A CN 201210595150 CN201210595150 CN 201210595150 CN 201210595150 A CN201210595150 A CN 201210595150A CN 103055124 A CN103055124 A CN 103055124A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- medicine composition
- traditional chinese
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating myelofibrosis. The composition of the traditional Chinese medicine comprises white paeony roots, oysters, radix ophiopogonis, white atractylodes rhizome, radix rehmanniae, radix pseudostellariae, multiflower knotweed roots, radix trichosanthis, desertliving cistanche, turtle shells, red paeony roots or acceptable carriers in pharmacy. The invention further discloses a preparation method of the composition of the traditional Chinese medicine. The composition of the traditional Chinese medicine has the effects of softening hardness to dissipate stagnation, invigorating the circulation of blood, regulating the stagnation of qi and the like, is used for treating myelofibrosis clinically, has a good curative effect, and is free from toxic and side effects.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically, relates to a kind of Chinese medicine composition for the treatment of myelofibrosis and preparation method thereof.
Background technology
Myelofibrosis refers to that the bone marrow hematogenesis tissue by fibrous tissue replacement, affects hemopoietic function, with the pathological state of the organ extramedullary hemopoiesiss such as spleen, liver.The primary disease pathogenesis is not yet illustrated, and the fibroblast proliferation of inferring primary disease is reactive and secondary arthritis and to the cytokine Increased sensitivity, and property or neoplastic hyperplasia occur to clone hematopoietic cell.
The most morbidities of myelofibrosis are in 50-70 year, onset is slow, early stage how asymptomatic or atypical symptom, about 30% patient diagnosis has only showed weak, hyperhidrosis, become thin, the hypermetabolism performance such as lose weight, or splenomegaly causes the vexed swollen sense of upper abdomen, upper left abdomen pain, poor appetite etc., some patients were chances on splenomegaly; The cardinal symptom of disease progression is the pressure symptom that anemia and splenomegaly cause, the performances such as low grade fever, perspiration, tachycardia increased the weight of due to metabolism was increased; Serious anemia and osteodynia are primary disease performance in late period, and severe patient has heating, and is hemorrhage, hyperuricemia, and individual patient can cause auditory dysesthesia because of the otica sclerosis.
Still lack at present the effective measures for the treatment of myelofibrosis, treatment should be processed accordingly according to lesion degree and the clinical manifestation of bone marrow fibrous tissue, and therapeutic purposes are mitigation symptoms, stops the fine progress of marrow.
The traditional Chinese medical science is thought: myelofibrosis belongs to " asthenia blood deficiency ", " gathering " category.Clinical manifestation is mainly lustreless complexion, spiritlessness and weakness, and spontaneous perspiration or night sweat, breast abdominal distention ask that the decreased food intake of receiving moves back, hepatosplenomegaly.Right healthy energy virtual loss is this sick origin, and excess caused by deficiency is its essence.The inventor thinks that treatment is upper should be on the basis of Replenishing QI and nourishing YIN, hard masses softening and resolving, and the row of invigorating blood circulation is stagnant.Its clinical efficacy is remarkable, deeply is subjected to the favor of extensive patients.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of myelofibrosis.
The present invention also aims to provide a kind of preparation method for the treatment of the Chinese medicine composition of myelofibrosis.
In order to realize purpose of the present invention, the invention provides a kind of Chinese medicine composition for the treatment of myelofibrosis, be to be made by effective ingredient and/or pharmaceutically acceptable carrier, described effective ingredient is to be made by weight by following raw material:
Effective ingredient preferably by following raw materials according by making by weight:
The present invention also provides the preparation method of this Chinese medicine composition, comprises the steps:
(1) getting respectively the Radix Paeoniae Alba, Concha Ostreae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, the Radix Rehmanniae, Radix Pseudostellariae, the Radix Polygoni Multiflori, Radix Trichosanthis, Herba Cistanches, Carapax Trionycis, Radix Paeoniae Rubra by proportioning decocts with water 2 times, 2 hours for the first time, 2 hours for the second time, filter merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.30 (80 ℃) that concentrating under reduced pressure becomes relative density, drying, be ground into fine powder, with pharmaceutically acceptable carrier granulation, capsule, tablet.
(2) Chinese medicine composition of the present invention can with pharmaceutically acceptable carrier, such as filler such as starch, microcrystalline Cellulose etc.; Binding agent such as vitamin derivative, starch etc.; Use by granule, capsule, tablet Oral administration.
Chinese medicine composition of the present invention has hard masses softening and resolving, and the effects such as row stagnates of invigorating blood circulation are used for the treatment of myelofibrosis clinically.
The specific embodiment
Following examples are used for explanation the present invention, but are not used for limiting the scope of the invention.
Embodiment 1: Chinese medicinal composition granules of the present invention
Getting Radix Paeoniae Alba 180g, Concha Ostreae 120g, Radix Ophiopogonis 280g, Rhizoma Atractylodis Macrocephalae 120g, Radix Rehmanniae 120g, Radix Pseudostellariae 180g, Radix Polygoni Multiflori 180g, Radix Trichosanthis 180g, Herba Cistanches 180g, Carapax Trionycis 120g, Radix Paeoniae Rubra 180g decocts with water 2 times, 2 hours for the first time, 2 hours for the second time, filter, merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.30 (80 ℃) that concentrating under reduced pressure becomes relative density, drying, be ground into fine powder, add lactose 200g, dextrin 300g, mixing sieves, with 75% ethanol wet granulation, dry, pack and get final product.
Embodiment 2: Chinese medicinal composition capsules agent of the present invention
Get Radix Paeoniae Alba 180g, Concha Ostreae 120g, Radix Ophiopogonis 280g, Rhizoma Atractylodis Macrocephalae 120g, Radix Rehmanniae 120g, Radix Pseudostellariae 180g, Radix Polygoni Multiflori 180g, Radix Trichosanthis 180g, Herba Cistanches 180g, Carapax Trionycis 120g, Radix Paeoniae Rubra 180g and decoct with water 2 times, 2 hours for the first time, 2 hours for the second time, filter, merging filtrate left standstill 48 hours, got supernatant, it is the thick paste of 1.30 (80 ℃) that concentrating under reduced pressure becomes relative density, drying is ground into fine powder, adds dextrin 250g, mixing is in the capsulae vacuus of packing into and get final product.
Embodiment 3: Chinese medicine composition tablet of the present invention
Getting Radix Paeoniae Alba 180g, Concha Ostreae 120g, Radix Ophiopogonis 280g, Rhizoma Atractylodis Macrocephalae 120g, Radix Rehmanniae 120g, Radix Pseudostellariae 180g, Radix Polygoni Multiflori 180g, Radix Trichosanthis 180g, Herba Cistanches 180g, Carapax Trionycis 120g, Radix Paeoniae Rubra 180g decocts with water 2 times, 2 hours for the first time, 2 hours for the second time, filter, merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.30 (80 ℃) that concentrating under reduced pressure becomes relative density, drying, be ground into fine powder, add starch 200g, microcrystalline Cellulose 100g, mixing sieves, with 75% ethanol wet granulation, tabletting, coating and get final product.
Although, above with a general description of the specific embodiments the present invention having been done detailed description, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (4)
1. a Chinese medicine composition for the treatment of myelofibrosis is to be made by effective ingredient and/or pharmaceutically acceptable carrier, it is characterized in that described effective ingredient is to be made by weight by following raw material:
2. Chinese medicine composition as claimed in claim 1, it is characterized in that described effective ingredient by following raw materials according by making by weight:
3. such as the arbitrary described Chinese medicine composition of right 1-2, it is characterized in that described Chinese medicine composition can be made into granule, capsule, tablet.
4. the preparation method such as the arbitrary described Chinese medicine composition of right 1-3 comprises the steps:
(1) getting respectively the Radix Paeoniae Alba, Concha Ostreae, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, the Radix Rehmanniae, Radix Pseudostellariae, the Radix Polygoni Multiflori, Radix Trichosanthis, Herba Cistanches, Carapax Trionycis, Radix Paeoniae Rubra by proportioning decocts with water 2 times, 2 hours for the first time, 2 hours for the second time, filter merging filtrate, left standstill 48 hours, get supernatant, it is the thick paste of 1.30 (80 ℃) that concentrating under reduced pressure becomes relative density, drying, be ground into fine powder, with pharmaceutically acceptable carrier granulation, capsule, tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210595150 CN103055124A (en) | 2012-12-20 | 2012-12-20 | Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210595150 CN103055124A (en) | 2012-12-20 | 2012-12-20 | Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103055124A true CN103055124A (en) | 2013-04-24 |
Family
ID=48098219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210595150 Pending CN103055124A (en) | 2012-12-20 | 2012-12-20 | Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103055124A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491277A (en) * | 2015-01-05 | 2015-04-08 | 杨茹芹 | Traditional Chinese medicine composition for treating myelofibrosis with blood stasis caused by qi-blood deficiency |
-
2012
- 2012-12-20 CN CN 201210595150 patent/CN103055124A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491277A (en) * | 2015-01-05 | 2015-04-08 | 杨茹芹 | Traditional Chinese medicine composition for treating myelofibrosis with blood stasis caused by qi-blood deficiency |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN101062221B (en) | Medicine for treating gastric ulcer and duodenal ulcer | |
| CN102512615A (en) | Traditional Chinese medicinal composition used for cancer recovery stage | |
| CN105497609A (en) | Traditional Chinese medicine composition tablets capable of relieving chemotherapeutic side effects on tumor patient | |
| CN106728770B (en) | Traditional Chinese medicine composition for tonifying kidney and replenishing vital essence and preparation method thereof | |
| CN103432412B (en) | Medicament for treating hyperplasia of mammary glands and preparation method thereof | |
| CN104825612A (en) | Medicine composition for treating gastritis and method for manufacturing medicine composition | |
| CN108283687B (en) | Medicine and food homologous traditional Chinese medicine composition for preventing and treating hypertension and cardiac injury and application thereof | |
| CN103463554A (en) | Pharmaceutical composition for treating malignant tumor, preparation method and application | |
| CN103055124A (en) | Traditional Chinese medicine composition for treating myelofibrosis and preparation method thereof | |
| CN101647961A (en) | Medicament for gastric cancer and esophagus cancer during postoperation and chemotherapy and preparation method thereof | |
| CN101954022B (en) | Chinese medicinal composition for treating lung cancer | |
| CN112717097A (en) | Traditional Chinese medicine composition for treating gastric cancer and preparation method thereof | |
| CN103446387B (en) | Traditional Chinese medicine composition for treating hyperthyroidism and preparation method thereof | |
| CN102861261B (en) | Chinese medicinal preparation for improving living quality of patient suffering from advanced malignant tumor | |
| CN104587214A (en) | Traditional Chinese medicine for preventing radiodermatitis caused by lung cancer radiotherapy | |
| CN104474327A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN104189770A (en) | Pharmaceutical composition for treating tuberculous pleuritis and preparation method thereof | |
| CN104399036A (en) | Medicine composition for treating chronic diarrhea and application of medicine composition | |
| CN102886017A (en) | Traditional Chinese medicine for treating ovarian cyst | |
| CN102793834B (en) | Traditional Chinese medicine for treatment of depression | |
| CN113368211A (en) | Traditional Chinese veterinary medicine composition for treating tumors of dogs and cats and preparation method thereof | |
| CN106236873A (en) | A kind of Chinese medicine composition treating disease of stomach | |
| CN104800457A (en) | Hard lump-resolving agent for treating gastric cancer and preparation method | |
| CN114681582A (en) | Oral traditional Chinese medicine composition for treating cold, preparation method and traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130424 |